Dear Editor, Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer among Caucasians with increasing incidence rates. 1 In advanced cases, such as incomplete excision or unresectable metastatic disease, the FDA approved PD-1 inhibitor cemiplimab is a valuable treatment option. 2 However, cemiplimab efficacy in the neoadjuvant setting remains unclear.Here we report a 55-year-old Caucasian male patient, who presented to our centre with an exulcerated tumour on the lower lip (Figure 1a,b). Within 4 months the lesion had rapidly grown to approximately 10 cm. Biopsy confirmed
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.